Company profile
Urovant Sciences company profile
Urovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Our lead product candidate is vibegron, an oral, once-daily, small molecule beta-3 agonist, being developed for overactive bladder (OAB), OAB in men with benign prostatic hyperplasia (BPH) and pain associated with irritable bowel syndrome (IBS). Urovant’s second investigational product candidate, URO-902, is a novel gene therapy for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy.
Business identity
- Website
- https://urovant.com/
- Contact email
- [email protected]
- Phone number
- +41 949-226-6029
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 101-250 employees
- Revenue range
- $1M-$10M
- Founded
- 2017-01-01, Year
Headquarters
- Headquarters
- Breíl, Grisons, Switzerland
- Country code
- CH
- Continent
- Europe